
Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD - HCPLive
In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL. Mepolizumab (Nucala) reduced total yearly systemic corticosteroid (SCS) exposure, particularly high-dose courses, in patients with COPD and type 2 inflammation receiving inhaled triple therapy, according to pooled phase 3 data presented at the American College of Chest Physicians (CHEST) 2026 Annual Meeting in Phoenix.¹,²Although treatment guidelines recommend SCS for COPD exacerbations, these agents are associated with complications in this population, prompting interest in targeted therapies capable of limiting their use.¹ Mepolizumab, a humanized monoclonal antibody targeting interleukin-5 (IL-5), is approved for patients with COPD and an eosinophilic phenotype.

















